This technology is a monoclonal antibody therapy to treat acute myeloid leukemia, myelodysplastic syndrome, and hematological myeloid malignancies and relapses.
This technology is an analog of the retired clinical psychotropic drug minaprine for the treatment of cognitive or behavioral disorders associated with neurodegenerative disorders.
This technology is a self-reportable measure of perceived cognitive change that can be used to track cognitive outcomes for treatment trials in neurologic populations.
